In the present mechanistic study, we sought to advance our understanding of the mechanism(s) governing the clinical impact of immunotherapy with Cat‐PAD by measuring the frequency of Fel d 1‐specific CD4+ T cells, their memory status, and their expression of Th1, and Th2‐associated chemokine receptors. The gene discussed is CD4; the disease is peripheral arterial disease.